All In Biotech

Drug Trial Radar · NCT06873334

Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease

A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

May 27, 2025

Primary completion

May 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Skyhawk Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD. This study includes men and women aged 25 and older who have HD confirmed by genetic testing and meet certain requirements for physical ability and independence.

Conditions

  • Huntington Disease
  • Huntingtons Disease

Interventions

  • SKY-0515Drug

    Study Drug Name (INN): SKY-0515 Type: Drug (small molecule) Dosage Level(s): Low, mid, high Route of Administration: Oral Dosage Frequency: Once daily Blinded Treatment Duration: 12 months Use: Experimental Sourcing: SKY-0515 will be provided centrally by the Sponsor or subsidiary, or designee Packaging and Labeling: Study drug will be provided in blinded bottles labeled as required per country requirement. All packaging and labeling operations for the study drug will be performed according to current Good Manufacturing Practice for Medicinal Products and the relevant regulatory requirements.

  • SKY-0515 PlaceboDrug

    Route of Administration: Oral Dosage Frequency: Once daily Blinded Treatment Duration: 12 months Use: Experimental Sourcing: SKY-0515 placebo will be provided centrally by the Sponsor or subsidiary, or designee Packaging and Labeling: Study drug will be provided in blinded bottles labeled as required per country requirement. All packaging and labeling operations for the study drug will be performed according to current Good Manufacturing Practice for Medicinal Products and the relevant regulatory requirements

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in blood mHTT protein levelsTime frame: 12 months
  2. Changes in brain volume measured through MRITime frame: 12 months
  3. Changes in UHDRSTime frame: 12 months

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • John Hunter Hospital

    New Lambton Heights, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • The University of Queensland

    Herston, Queensland, Australia

  • Flinders Medical Centre

    Adelaide, South Australia, Australia

  • Launceston General Hospital

    Launceston, Tasmania, Australia

  • Calvary Health Care Bethlehem

    Caulfield South, Victoria, Australia

  • The Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • The Perron Institute for Neurology and Translational Science (Perron Institute)

    Nedlands, Western Australia, Australia

  • Huntington's Disease Association

    Auckland, New Zealand

  • Auckland City Hospital

    Auckland, New Zealand

  • Christchurch Neurology Trials Limited

    Christchurch, New Zealand

  • Wellington Hospital

    Wellington, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.